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Antiretroviral Therapy
Persistence of Macrocytosis after
Discontinuation of Zidovudine
in HIV-Infected Patients
Inski Yu, MD1, Richard N. Greenberg, MD2, Timothy N. Crawford, PhD3,
Alice C. Thornton, MD2, and Thein Myint, MBBS2
Abstract
The duration of macrocytosis after stopping zidovudine (ZDV) is unknown. Among 104 HIV-infected patients treated with ZDV
for more than 1 year, 84 patients had macrocytosis at ZDV discontinuation. The median mean corpuscular volume (MCV) was
114.6 fL (range 100-128 fL). Patients were divided into 2 groups: those who did (resolved macrocytosis, n ¼ 36) and did not
(persistent macrocytosis, n ¼ 48) normalize MCV at 3 to 6 months after ZDV discontinuation. Alcohol use (P ¼ .02), smoking
(P ¼ .03), and lower (but within normal range) folic acid levels (P ¼ .05) were related to the persistence of macrocytosis.
A persistence of macrocytosis was observed in 57% at 3 to 6 months, 38% at 1 year and 37% at 2 years after ZDV therapy had
stopped. Duration of ZDV therapy did not have an effect on the persistence of macrocytosis (P ¼ .73). The median time for the
MCV to normalize after stopping ZDV was 12.5 months.
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Introduction
Macrocytosis, defined as mean corpuscular volume (MCV)
100 fL (normal 79-98 fL), is broadly categorized as mega-
loblastic (eg, associated with folate or cobalamin deficiency) or
normoblastic (eg, associated with alcoholism, liver disease, and
certain drugs including zidovudine [ZDV]).1 Up to 88% of
HIV-infected patients treated with ZDV are reported to have
macrocytosis.2,3 Zidovudine, a thymidine analogue nucleoside
reverse transcriptase inhibitor, competes with natural deoxynu-
cleoside triphosphates for binding to HIV reverse transcriptase
as it converts HIV RNA into DNA. Competition with the latter
can result in impaired synthesis of the erythrocyte precursor in
the bone marrow, consequently resulting in macrocytosis.4 The
mechanism causing macrocytosis probably involves DNA bio-
synthetic changes5 and changes in erythrocyte plasma mem-
brane cholesterol and fatty acid and may be a manifestation of
mitochondrial dysfunction.4,6
Mean corpuscular volume increases by a mean of 3% at
week 4 and 14% at 12 weeks after starting ZDV. Mean corpus-
cular volume can be used as a marker for adherence to ZDV
containing therapy.3 Some HIV-infected patients show persis-
tence of macrocytosis with or without anemia after disconti-
nuation of ZDV. There is limited literature on duration of
persistence of macrocytosis after discontinuation of ZDV. This
study characterizes the duration of macrocytosis after discon-
tinuation of ZDV.
Methods
This is a retrospective cohort study approved by the University
of Kentucky Institutional Review Board. We reviewed the clin-
ical data of HIV-infected patients 18 years old obtained from
the University of Kentucky clinic, with (1) continuous expo-
sure to ZDV 1 year from January 01, 2004, to December 31,
2013, and (2) availability of the clinical laboratory data at least
3 months after discontinuation of ZDV. Zidovudine 300 mg
twice daily as a fixed dose was prescribed to patients as
Retrovir (GlaxoSmithKline), Combivir (GlaxoSmithKline), or
Trizivir (ViiV Healthcare). Mean corpuscular volume and
hemoglobin were recorded at the following time lines: 1 year
prior to discontinuation, at discontinuation, 3 to 6 months
later, and approximately 1 year and 2 years after discontinua-
tion. Aspartate aminotransferase (AST) and alanine
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aminotransferase (ALT) levels were recorded at 3 to 6 months
after discontinuation. Our data also included, if performed,
hepatitis B surface antigen, hepatitis C antibody, thyroid-
stimulating hormone (TSH), folic acid, vitamin B12 level,
venous lactic acid level, and presence of fatty liver by ultra-
sound or computed tomography scan of abdomen performed at
any time during the study period.
The stop date of ZDV was defined as 1 month after the last
prescription date or the documented date of the clinic visit
when ZDV was stopped. Suppressed viral load was defined
as <200 copies/mL. Anemia was defined as hemoglobin
<13.5 g/dL in males and <12 g/dL in females. There was no
specific criterion for alcohol use or smoking.
Statistical Analysis
For the entire study sample, descriptive statistics were performed.
Means, standard deviations, medians, ranges, and interquartile
ranges (q1 and q3) were recorded for all continuous variables and
frequencies and percentages for all categorical variables. For
analysis of the relationships of variables between resolved macro-
cytosis (RM) group and persistent macrocytosis (PM) group,
bivariate analyses were performed using the chi-square test or the
Fisher exact test for categorical variables and the Wilcoxon tests
for continuous variables. Kaplan-Meier curves were produced to
determine median time to normalize macrocytosis, and log-rank
tests were used to compare curves. To normalize macrocytosis
analysis, participants with PM or those lost to follow up were
censored. SAS version 9.4 (SAS Institute) was used for statistical
analysis. The level of significance was defined as P < .05 (2 sided)
unless otherwise specified.
Results
One hundred and four patients met the abovementioned cri-
teria. The mean age was 46 years (standard deviation ¼ 9.9
years), 83% were male, and 72% were white. The median
treatment duration of ZDV was 4.6 years (range, 1-14 years).
Eight (8%) patients were on ZDV 10 years, 30 (29%)
patients between 5 and 10 years, and 66 (63%) patients
<5 years. Macrocytosis was present in 81% (n ¼ 84/104)
1 year prior to stopping ZDV and 86% (n ¼ 89/104) at the
time of stopping ZDV.
At the Time of ZDV Discontinuation
Among the 104 patients who met the abovementioned criteria,
89 HIV-infected patients had macrocytosis. Of the 89
patients, 5 were excluded in the analysis due to their detect-
able viral load 200 copies/mL with normal MCV at the time
of ZDV discontinuation, suggesting noncompliance. Fifty-
nine (70%) of 84 patients were switched to tenofovir
(TDF)–emtricitaine-based regimens, 21 (25%) to abacavir
(ABC)–lamivudine (3TC )-based regimens, 3 patients to
nucleoside reverse transcriptase inhibitor (NRTI)-sparing
regimens. One patient did not continue HIV medication after
stopping ZDV. The mean MCV was 115 fL at the time of
ZDV discontinuation, 103 fL at 3 to 6 months, 99 fL at 1 year,
and 98 fL at 2 years after ZDV discontinuation.
Among 84 patients with viral load <200 copies/mL after
ZDV discontinuation, 57% (48 of 84) had macrocytosis at 3
to 6 months, 38% (31 of 81) at 1 year, and 37% (29 to 79) at
2 years. Of the 44 patients with MCV  115 fL at the time of
stopping ZDV, macrocytosis persisted in 73% (32 of 44) at 3 to
6 months, 45% (20 of 44) at 1 year, and 47% (20 to 43) at
2 years. Of the 40 patients with an MCV <115 fL, macrocytosis
persisted in 40% (16 of 40) at 3 to 6 months (P ¼ .003 com-
pared to MCV > 115 fL), 30% (11 of 37) at 1 year (P ¼ 0.15),
and 25% (9 of 36) at 2 years after stopping ZDV (P ¼ .048).
The median MCV of 84 HIV-infected patients with macro-
cytosis at the time of ZDV discontinuation was 114.6 (range
100-128 fL). Of the 84 patients, 16% (n¼ 14) had anemia, 12%
(n ¼ 10) had chronic hepatitis B infection, 8% (n ¼ 7) had
chronic hepatitis C infection, and 1 patient had coinfection with
chronic hepatitides B and C. In 2 patients, the venous lactic
acid levels at the time of ZDV discontinuation were within the
normal range. Among 8 patients on ZDV  10 years, 2 had
normal MCV at the time of discontinuation and 6 had normal
MCV at 3 to 6 months after ZDV discontinuation.
At 3 to 6 Months after ZDV Discontinuation
Eighty-four virologcially suppressed HIV-infected patients
with macrocytosis at the time of ZDV discontinuation were
divided into 2 groups, the groups that did (RM, n ¼ 36) and
did not (PM, n ¼ 48) normalize their increased MCV at 3 to
6 months. Comparison of the 2 groups is shown in Table 1.
HIV-infected patients in the PM group were more likely to
use alcohol (50% versus 25%, P ¼ .02), smoke (69% versus
44%, P¼ .03), and have lower folic acid levels (median¼ 13.5
versus 18.1, P ¼ .05) compared to the HIV-infected patients in
the RM group. The presence of coinfection with hepatitis B,
hepatitis C, elevated transaminases (AST > 40 and ALT > 41),
a fatty liver, and decreased vitamin B12 levels were not statis-
tically significant between the 2 groups.
At 1 Year and 2 Years after ZDV Discontinuation
At 1-year follow-up after discontinuation of ZDV, macrocyto-
sis persisted in 38% (31 of 81) of enrolled patients, 19% (6 of
31) of those with macrocytosis at 1 year had anemia. Of the
patients, 66% (31 of 47) from the PM group had macrocytosis
at 1 year, whereas no patient from the RM group had PM at
1 year (P < .001).
At the 2-year follow-up, 37% (29 of 79) of patients had
macrocytosis. Seven (24%) of 29 patients had anemia. Of those
patients, 55% (26 of 47) with macrocytosis at 3 to 6 months
(PM group) had macrocytosis at 2 years after stopping ZDV,
whereas 9% (3 of 32) of those who had previously RM (RM
group) had macrocytosis at 2 years (P < .0001). Overall, the
median time for MCV to normalize was 12.3 months (95%
confidence interval: 7.6-14.4; see Figure 1). Time to
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normalization was longer for smokers compared to nonsmokers
(P ¼ .005; Figure 2).
Discussion
Zidovudine was initially synthesized as a potential antineo-
plastic agent in 1964.7 It was never approved for use in
humans as cancer chemotherapy. Zidovudine was used as
monotherapy for HIV treatment in the 1980s.8 It has contin-
ued as combination regimens for HIV treatment and in the
prevention of perinatal HIV transmission.9,10 It is still used as
a first-line antiretroviral regimen in resource-constrained
setting.10 Apart from macrocytosis and bone marrow toxicity,
ZDV can cause lipodystrophy, lactic acidosis, myopathy, and
liver toxicity.9–11 Zidovudine can cause mitochondrial toxi-
city that can lead to several mitochondrial disorders. It is
known that mitochondrial genetic polymorphisms can lead
to individual NRTI toxicity.12 Macrocytosis may be a marker
of treatment-related mitochondrial dysfunction in persons on
ZDV.4 Persistent macrocytosis after ZDV treatment may be a
marker for the presence of such mitochondrial DNA muta-
tions; as such, it might elicit concern for more severe mito-
chondrial dysfunction with the use of other NRTIs.
To our knowledge, this is the first study to review the risk
factors associated with the persistence of macrocytosis after
discontinuation of ZDV.
The median treatment duration of ZDV in our study popu-
lation was 4.6 years (range, 1-14 years). Macrocytosis was
Table 1. Comparison of Resolved Macrocytosis (RM) Group and Persistent Macrocytosis (PM) Group at 3 to 6 Months after Stopping ZDV.a
Total Patients (N ¼ 84)
Resolved Macrocytosis (RM)
group (n ¼ 36)
Persistent Macrocytosis
(PM) group (n ¼ 48) P Value
Average age, mean (SD) 46.8 (10.6) 44.8 (11.7) 48.2 (9.5) .15
Race, n (%)
Caucasian 67 (80) 27 (75) 40 (83) .35
African American 8 (10) 4 (11) 4 (8)
Hispanic 9 (11) 5 (14) 4 (8)
Sex, male, n (%) 71 (85) 28 (78) 43 (90) .14
Years on ZDV, median (q1, q3) 4.0 (2.0, 6.0) 4.6 4.6 .73
Anemia at 3 to 6 months, N (%) 11 (13) 5 (14) 7 (15) .93
Smoking—yes, n (%) 48 (57) 16 (44) 33 (69) .03
Alcohol use—yes 32 (38) 9 (25) 24 (50) .02
Chronic hepatitis B—yes 10 (12) 3 (8) 7 (15) .38
Chronic hepatitis C—yes 7 (8) 1 (3) 6 (13) .11
AST >40 U/L, n (%) 15 (18) 5 (14) 10 (21) .41
ALT >41 U/L, n (%) 31 (37) 12 (33) 19 (40) .56
TSH level, mIU/mL, median (q1, q3) 1.7 (1.25, 2.32), N ¼ 74 1.73 (1.15, 2.20), n ¼ 32 1.70 (1.388, 2.34), n ¼ 42 .81
Vitamin B12 level, ng/L, median (q1, q3) 469.0 (289.0, 734.0), N ¼ 39 502.0 (277.0, 766.0), n ¼ 21 415.5 (311.0, 629.0), n ¼ 18 .79
Folic acid level, ng/L, median (q1, q3) 15.4 (10.9, 20.0), N ¼ 29 18.1 (11.3, 20.0), n ¼ 15 13.5 (9.2, 17.3), n ¼ 14 .05
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; SD, standard deviation; TSH, thyroid-stimulating hormone; ZDV, zidovudin.
aN ¼ 84.
Figure 1. Time to resolution of macrocytosis (normalization); overall
median time to resolution was 12.3 months.
Figure 2. Time to resolution of macrocytosis stratified by smoking
status.
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present in 86% (n¼ 89 of 104) at the time of stopping ZDV. Of
the patients, 14% did not develop macrocytosis despite long-
term ZDV. The MCV decreased by a mean of 11% at 3 to
6 months, 14% at 1 year, and 15% at 2 years after ZDV dis-
continuation. The duration of ZDV did not seem to affect the
persistence of the macrocytosis (P ¼ .73). Eight patients who
were on ZDV 10 years normalized MCV within 3 to 6 months
after stopping ZDV. The patients with an MCV > 115 fL at
discontinuation of ZDV were more likely to have PM up to 2
years later. The patients in this cohort were switched from ZDV
to different NRTI-based regimens, and these new treatments
could have had an unidentified effect on their MCV. Alcohol
use, smoking, and lower (but within normal limit) folic acid
levels (median 11.1 ng/mL) appeared significant for persis-
tence of macrocytosis. However, there were no patients with
folic acid deficiency in the PM group. The duration of ZDV,
anemia, smoking, TSH, and vitamin B12 levels, elevated trans-
aminases, and presence of fatty liver were not statistically sig-
nificant. Five patients with a normal MCV had abnormal TSH
levels (2 low and 3 high, normal 0.-4 mIU/mL).
Limitations of this study include the small number of study
patients, only a single center, a retrospective study, and a study
in which the laboratory data were not obtained at regular inter-
vals. Also there was no quantification for alcohol use, smoking,
or bone mineral density testing after ZDV was stopped.
Changes in bone density have been suggested a marker for
mitochondrial toxicity for those taking an NRTI.13
In conclusion, we found a PM in 57% of 84 HIV-infected
patients at 3 to 6 months, 38% of 81 patients at 1 year, and 37%
of 79 patients at 2 years after ZDV therapy had stopped. Dura-
tion of ZDV therapy did not appear to have an effect on the
persistence of macrocytosis (P ¼ .73). The median time for
the MCV to normalize after ceasing ZDV was 12.5 months.
The higher the MCV, the longer it took to normalize. Alcohol
use, smoking, and lower folic acid levels were related to
persistence of macrocytosis. Of the patients, 55% continued
to have PM 2 years after stopping ZDV if their MCV did not
normalize by 3 to 6 months after discontinuing ZDV.
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